Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

March 25, 2020March 25, 2020

Study to Test MRI Technique for Possible Early Parkinson’s Diagnosis

News

A clinical study will test the potential of a specific magnetic resonance imaging (MRI) technique to diagnose Parkinson’s disease at early stages. The 18-month project, supported by a grant ... Read more

March 23, 2020March 23, 2020

Dyskinesia Trial Testing Dipraglurant Postponed Due to COVID-19

News

A Phase 2/3 trial (Study 301) testing Addex Therapeutic’s candidate dipraglurant for people with levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID) has been postponed — until further notice — due ... Read more

March 9, 2020March 9, 2020

Enrollment Ongoing in PROPEL Trial for Prevail’s Gene Therapy PR001

News

Enrollment in the Phase 1/2 PROPEL trial, evaluating the safety, tolerability, and early efficacy of PR001 — a one-time gene therapy — for Parkinson’s disease associated with mutations in ... Read more

March 2, 2020March 2, 2020

Sangamo, Biogen Team Up to Develop Gene Therapies for Neuromuscular Diseases

News

Sangamo and Biogen are teaming up to develop gene therapies for Parkinson’s and Alzheimer’s disease, as well as another neuromuscular disease target and up to nine undisclosed neurological disorders. The ... Read more

February 27, 2020February 27, 2020

CDNF Safe in Advanced Parkinson’s, Trial Results Show

News

Treatment with cerebral dopamine neurotrophic factor (CDNF), developed by Herantis Pharma, was safe and well-tolerated among patients with advanced-stage Parkinson’s disease, according to topline results from a Phase1/2 clinical ... Read more

February 24, 2020February 24, 2020

Annovis Given US Patent for Potential Parkinson’s Treatment Expected to Enter Phase 2 Trial

News

Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, ... Read more

February 19, 2020February 19, 2020

Motion Machine’s Ability to Ease Motor Symptoms in Parkinson’s Entering Trial in Australia

News

A trial in Australia will test a motion machine, called the Reviver, to understand whether it can improve balance, mobility and sensory-motor coordination in people with moderate to advanced ... Read more

February 6, 2020February 11, 2020

Collaboration Formed to Develop New Radiochemicals for Diagnosing, Treating Brain Diseases

News

A collaborative effort between Fuzionaire Diagnostics, McGill University and The Neuro (Montreal Neurological Institute-Hospital) will foster the development of a new class of radioactive molecules — called radiochemicals — ... Read more

February 4, 2020February 4, 2020

FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia

News

VistaGen Therapeutics will begin a Phase 2 clinical trial to evaluate its lead candidate AV-101 as a potential treatment to reduce dyskinesia (abnormal involuntary movements) induced by levodopa in ... Read more

February 3, 2020February 3, 2020

High Blood Levels of Urate May Help Protect Dopamine-Producing Neurons in Men With Parkinson’s, Study Suggests

News

High levels of urate in the blood may help preserve dopamine-producing neurons and be used as a biomarker of positive outcomes in men newly-diagnosed with Parkinson’s disease, a study ... Read more

Pin It on Pinterest